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When it is dark enough, you can see the stars. 
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ABSTRACT 
 
Introduction: Endometriosis is a common benign gynecological disease where 
endometrial tissue forms lesions outside the uterine cavity. Endometriosis is estimated 
to affect about 10% of women of reproductive age, rising to 20-40% in patients with 
infertility, with a significant impact on physical, mental and social well-being of those 
affected. Today there is no cure for this disease and the most common medical 
treatments are not suitable for long term treatment due to side-effects.  
Although endometriosis is a well-known disease, the pathogenesis remains unclear. 
The most accepted theory about the pathogenesis is Sampson´s theory about retrograde 
menstruation. However, different properties, such as adhesion, invasion and 
proliferation of the shed menstrual cells seem to play an important role in the 
development of endometriosis. Also, altered immune surveillance, stem cells and 
genetic predisposition could be involved in the pathogenesis.  
Aims: The overall aim of this thesis was to study the aetiology and pathophysiology of 
endometriosis, specifically the inflammatory profile in the follicular fluid of in vitro 
fertilization (IVF) patients and adhesion, attachment and invasion factors in 
endometriosis. Furthermore, the aim was to investigate the genetic background of 
endometriosis and a possible genetic linkage to rheumatoid arthritis (RA) and ovarian 
cancer. 
Results: We found that women with endometriosis undergoing IVF have lower levels 
of anti-mullerian hormone (AMH) and a lower fertilization rate. These women also 
have an increased inflammatory profile in the follicular fluid. We observed genetic 
association of two RA-associated SNPs in CCL21 and HLA-DRB1 in women with 
moderate/severe disease. However, we could not observe any association of the ovarian 
cancer associated SNPs in the BNC2 gene. In addition, we found expression of ApoE, 
ITGB2, ITGB7, LAMC1, CD24 and JAM-1, in endometrium from healthy controls, 
endometrium from endometriosis patients and in endometriomas.  
Conclusions: Our results support a strong inflammatory component in endometriosis, 
which may affect the ovarian reserve and lead to infertility problems. Furthermore, 
genetic associations in inflammatory related genes were found in women with 
moderate/severe disease. An aberrant expression of factors involved in adhesion, 
attachment and invasion may be important in the establishment of endometriotic lesions 
and may at least partly be regulated by inflammatory mediators. 
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1 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Endometrios är en vanlig sjukdom som drabbar ca 10% av kvinnor i reproduktiv ålder. 
Sjukdomen är associerad med bäckensmärtor och infertilitet. Endometrios består av 
små härdar av endometrievävnad (livmodervävnad) som fäster utanför livmodern. 
Orsaken till sjukdomens uppkomst är fortfarande oklar, men olika teorier finns. Man 
vet att under menstruationen förekommer en retrograd blödning hos de flesta kvinnor, 
vilket innebär att blod och endometrievävnad kommer ut i bukhålan. I normala fall tas 
blodet och vävnaden om hand av immunceller, men hos kvinnor som utvecklar 
endometrios verkar detta inte ske. Vävnaden fäster sedan till bl.a. bukväggen och 
äggstockarna, där den regleras hormonellt och blöder såsom det normala endometriet 
under menscykeln. Man tror att även andra faktorer spelar en roll i utvecklingen av 
sjukdomen. Vävnaden som fäster på bukväggen/äggstockarna tros ha förändrade 
egenskaper som gör att dessa celler kan överleva och fästa till/invadera annan vävnad. 
Dessutom har man sett att kvinnor med endometrios har en ökad inflammatorisk 
aktivitet i bukvätskan, som skulle kunna påverka utvecklingen av endometrios och 
fertiliteten. Visst genetiskt anlag skulle också kunna göra att man lättare utvecklar 
sjukdomen. 
 
Vi har studerat resultat av assisterad befruktning (IVF) hos kvinnor med endometrios i 
jämförelse med friska kvinnor med infertilitet på grund av skadade äggledare. 
Dessutom har vi tittat på inflammatoriska markörer i follikelvätskan, dvs. den vätska 
som omger de mognande äggen i äggstocken. Vi såg att kvinnorna med endometrios 
hade ökade nivåer av pro-inflammatoriska markörer (TNF-α, IL-15 and GM-CSF) och 
sänkta nivåer av en anti-inflammatorisk markör (IL-10). Dessa kvinnor hade även lägre 
nivåer av AMH, en markör för äggreserven i äggstocken, i follikelvätska och serum, 
vilket tyder på att kvinnor med endometrios har färre ägg som kan mogna och bli 
befruktade. Vi kunde även se att kvinnor med endometrios svarade bra på IVF 
behandlingen, men att befruktning av deras ägg var sämre än i kontrollgruppen. 
 
Kvinnor med endometrios har en ökad inflammatorisk aktivitet och man har sett att 
dessa kvinnor i en högre utsträckning drabbas av autoimmuna sjukdomar, bl.a. 
reumatism. Samband har hittats mellan olika genetiska variationer och olika 
autoimmuna sjukdomar. Vi ville därför undersöka om de genetiska variationer som är 
kopplade till reumatism även är kopplade till endometrios. Vi valde att titta på 
variationer i gener som är involverade i inflammation, men inget samband kunde hittas 
mellan endometrios och dessa variationer. Däremot, när vi delade upp kvinnorna med 
endometrios i två grupper beroende på sjukdomens svårighetsgrad, såg vi en koppling 
mellan variationer i två olika gener (CCL21 och HLA-DRB1) och moderat/svår 
endometrios.   
 
Ett samband mellan endometrios och ovarialcancer har också hittats. Det är möjligt att 
endometrios på äggstockarna skulle kunna omvandlas direkt till cancer. En annan teori 
är att endometrios och ovarialcancer delar samma mekanismer eller genetiska 
variationer som gör att drabbade kvinnor lättare utvecklar sjukdomarna. Genetiska 
variationer i genen BNC2 har tidigare kopplats till ovarialcancer och dessa variationer 
 2 
skulle även kunna vara kopplade till endometrios. I vår studie kunde vi inte hitta någon 
koppling till sjukdomen. 
 
Vi har även studerat olika faktorer som påverkar cellernas förmåga att fästa och 
invadera annan vävnad. Vi såg att alla dessa faktorer (ApoE, ITGB2, ITGB7, LAMC1, 
CD24 and JAM-1) fanns i endometrium från friska kvinnor, i endometrium från 
kvinnor med endometrios och i endometriosvävnad. Olika uttryck av dessa faktorer hos 
friska kvinnor och kvinnor med endometrios skulle kunna göra att den vävnad som 
hamnar i buken under mensen kan fästa och invadera och därmed leda till att 
endometrioshärdar bildas.  
 
Endometrios är en komplicerad sjukdom, där många olika faktorer spelar in. Därför är 
det svårt att veta vad som egentligen orsakar sjukdomen och hur man ska behandla den 
på bästa sätt. Dessutom påverkas kvinnorna som drabbas av endometrios inte bara 
fysiskt, utan även psykiskt. Fler studier behövs för att undersöka hur endometrios 
uppkommer och mina studier är bara ett steg på vägen. Genom att få pusselbitar från 
olika studier, hoppas jag att pusslet kan bli komplett så att kvinnorna med endometrios 
kan få ett liv utan smärtor och infertilitet. 
 
   3 
2 INTRODUCTION 
 
2.1 ENDOMETRIOSIS 
Endometriosis is a benign gynecological disease, characterized by the presence of 
endometrial stroma and glands outside the uterine cavity. It occurs mostly as peritoneal 
surface lesions, ovarian lesions and deeply infiltrating lesions of the rectovaginal 
septum or gut. Endometriosis located within the muscular wall of the uterus is called 
adenomyosis.  Endometriosis is associated with chronic pelvic pain, dysmenorrhoea, 
dyspareunia, infertility and inflammation, although not all women with endometriosis 
are symptomatic.   
 
Endometriosis affects about 10% of women of reproductive age (reviewed in (Eskenazi 
and Warner, 1997)), from all ethnic and social groups. About 20-40% (1994, Strathy, et 
al., 1982, Verkauf, 1987) of women with infertility have endometriosis. Thus, the 
disease also has a major impact on general physical, mental and social well-being 
(Jones, et al., 2004, Lorencatto, et al., 2006). In addition, endometriosis is a large 
healthcare problem and imposes a substantial economic burden on society. Simoens et 
al. estimated that the annual cost of endometriosis in the USA in 2002 was about 22 
billion USD  (Simoens, et al., 2007). However, not only hospital visits are costly, but 
also indirect cost, such as time lost from work due to the disease. Hummelshoj et al. 
reported that 78% of women with endometriosis in UK lose a mean of 5.3 days of work 
per month, due to their disease (Hummelshoj, et al., 2006). 
 
 
2.1.1 Diagnosis and staging of endometriosis 
Establishing a diagnosis of endometriosis is difficult. Therefore, the time between onset 
of symptoms and diagnosis can take several years. In USA and UK, the delay of 
diagnosis is about 7-12 years (Hadfield, et al., 1996). Today, laparoscopy is the gold 
standard for diagnosis. Noninvasive techniques, such as ultrasound and magnetic 
resonance imaging (MRI), could also be used to diagnose some types of endometriosis 
(reviewed in (Brosens, et al., 2004)). Currently, there are no reliable biomarkers for the 
diagnosis or prognosis of endometriosis. Different markers in serum and peritoneal 
fluid, including cancer antigen 125 (CA125) (Colacurci, et al., 1996) and cytokines 
such as Interleukin 6 (IL-6) and tumor necrosis factor (TNF)-α (Bedaiwy, et al., 2002), 
have been suggested. Although promising results have been shown (Ceyhan, et al., 
2010, Seeber, et al., 2010), further studies are needed to evaluate the relevance of these 
biomarkers for diagnosis. Interestingly, a recent study by Tokushige et al. demonstrated 
that Cytokeratin-19 in urine could be a possible biomarker (Tokushige, et al., 2011). 
 
The severity of endometriosis is assessed by the revised classification system 
developed by the American Society of Reproductive Medicine (ASRM) (1997), using 
four stages (I-IV or minimal to severe disease), on the basis of type, location, 
appearance, depth of invasion and extent of disease. However, there is no correlation 
between stage and severity of pain symptoms or prediction of infertility treatment. 
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The extent of endometriosis varies from small lesions to large ovarian endometriotic 
cysts (endometriomas or chocolate cysts) with extensive fibrosis and adhesions leading 
to distortion of the pelvic anatomy. Endometrial lesions are mainly divided into three 
types; 1) peritoneal lesions on the peritoneal surface, 2) deep infiltrating lesions located 
at least five mm under the peritoneum and 3) ovarian endometriotic cysts. The lesions 
typically appear as red, black/blue or white, representing different steps in the 
evolutionary process of endometriosis (reviewed in (Nisolle and Donnez, 1997)). Red 
lesions are considered to be the first stage, as they are most active and highly 
vascularized. When these lesions bleed and accumulate blood, they turn into black/blue 
lesions, a characteristic for advanced endometriosis. White lesions are considered 
healed and latent, but may remodel into more active lesions (D'Hooghe, et al., 1992).  
 
Infiltration of nerve fibers (Tokushige, et al., 2006, Zhang, et al., 2010) and 
neuroendocrine cells (Wang, et al., 2010) have been observed in endometriotic lesions.  
Over-expression of nerve growth factor (NGF) was found in peritoneal fluid from 
women with endometriosis, which also promoted neurite outgrowth in vitro (Barcena 
de Arellano, et al., 2010). Interestingly, Al-Jefout et al. observed that detection of nerve 
fibers in endometrial biopsies provided a reliable diagnosis of endometriosis (Al-Jefout, 
et al., 2009). 
 
 
2.1.2 Treatment of endometriosis 
Endometriosis can be treated by surgery and/or pharmacologically, with three aims: to 
reduce pain, increase fertility/pregnancy and delay recurrence as long as possible. Most 
pharmacological treatments are based on hormonal suppression, leading to a hypo-
estrogenic state and the elimination or reduction in size of the endometriotic lesions. 
Pharmacological treatment includes progestins, danazol, gonadotropin-releasing 
hormone (GnRH) analogues, the levonorgestrel-releasing intrauterine system (lng-IUS) 
and oral contraceptives. Some treatment, like the lng-IUS (Mirena) only alleviates pain, 
but does not affect the disease (reviewed in (Bahamondes, et al., 2007)). Hormonal 
suppression with certain drugs, such as GnRH, for a longer time period, leads to 
undesirable side effects due to a systemic estrogen deficiency.  
 
Other pharmacological drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) 
are widely used to treat chronic pain in endometriosis patients. Regression of lesion 
size in rats has been observed during treatment with an aromatase inhibitor (letrozole) 
and reduction of pain symptoms in humans has been observed in the clinic with 
treatment of either aromatase inhibitors alone or in combination with oral 
contraceptives (Seal, et al., 2011, Verma and Konje, 2009). 
 
Alternative non-hormonal targets for treatment of endometriosis have been suggested, 
such as immune-modulators, anti-angiogenic agents and anti-inflammatory drugs. For 
example, treatment with anti-TNF antibody has been shown to reduce the extent of 
endometriosis in baboons (Falconer, et al., 2006).  
 
Surgical removal of endometriotic lesions aims at reducing pain by removing the 
endometriotic tissue and to restore normal pelvic anatomy. Although surgery 
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effectively alleviates pain (reviewed in (Jacobson, et al., 2009)), endometriotic lesions 
usually recur within a few years. Also, surgery of ovarian endometriosis is associated 
with decreased ovarian reserve (Ragni, et al., 2005). 
 
 
2.1.3 Is endometriosis one disease or several? 
Different types of endometriosis can be observed in the pelvis. It is not clear if 
peritoneal endometriosis is an early stage of the disease, later developing into ovarian 
and deep infiltrating endometriosis, or if these types of endometriosis could represent 
three different diseases with different etiologic mechanisms (reviewed in (Nisolle and 
Donnez, 1997)).  It has also been speculated whether mild endometriosis should be 
regarded as a natural condition occurring in all women (Koninckx, et al., 1994). Gene 
expression studies have reported differences between ovarian endometriosis and deep 
infiltrating endometriosis, indicating that the local endocrine control and hormonal 
microenvironment could differ between these two types of disease (Matsuzaki, et al., 
2006). This is strengthened by varied expression of aromatase between different types 
of endometriosis (Heilier, et al., 2006). A genetic study further supports this theory by 
reporting genetic association with protein tyrosine phosphatase non-receptor type 22 
(PTPN22) and endometriosis, but only in women with moderate/severe disease 
(Gomes, et al., 2010).  
 
 
2.2 PATHOGENESIS OF ENDOMETRIOSIS 
The pathogenesis of endometriosis is not fully understood. Several different theories 
have been suggested: 
 
• The implantation/ transplantation theory indicates the development of 
endometriosis by the deposit of viable endometrial cells into the peritoneal 
cavity by retrograde menstruation through the fallopian tubes, where the 
endometrial cells are able to attach and grow (Sampson, 1927). 
 
• The induction theory suggests that degenerating endometrium in the abdominal 
cavity releases factors and thus inducing a metaplastic process in mesenchymal 
cells, leading to endometriosis (Levander and Normann, 1955).  
 
• According to the in situ development theory ectopic endometrium develops in 
situ from local tissue, including remnants of the Wolffian and Müllerian ducts 
(Lauchlan, 1972).  
 
The most widely accepted theory today is the implantation theory proposed by 
Sampson (Sampson, 1927), which is supported by several observations. Firstly, women 
with endometriosis have been shown to have shorter cycles (Arumugam and Lim, 
1997) and heavier menstrual flow (Vercellini, et al., 1997). Secondly, viable cells in the 
endometrial effluent have also been observed (Keettel and Stein, 1951). In addition, 
Ridley and Edwards showed that endometrial tissue, collected from menstrual 
endometrium, could attach and proliferate in ectopic locations (Ridley and Edwards, 
1958). Thirdly, patients with obstructed menstrual outflow have an increased risk of 
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developing endometriosis (Olive and Henderson, 1987). This has also been confirmed 
by D´Hooghe et al., who showed that cervical ligation in baboons leads to 
endometriosis (D'Hooghe, et al., 1994). Furthermore, a correlation between the amount 
of endometrium used for induction and the extent of endometriosis was observed in 
baboons (D'Hooghe, et al., 1995). These observations strongly indicate an important 
role of retrograde menstruation in the development of endometriosis. 
 
It is well known that retrograde menstruation occurs in most women, with an incidence 
of 76-90% (Halme, et al., 1984, Liu and Hitchcock, 1986), but not all women develop 
endometriosis. Therefore, the development of endometriosis is likely to not only 
involve retrograde menstruation, but also other factors such as adhesion and invasion of 
endometrial cells, proliferation, angiogenesis and immune escape, seen in figure 1. 
Furthermore, a genetic predisposition seems to be involved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Different factors involved in the pathogenesis of endometriosis. (Reprinted from Matarese et 
al. Trends Mol Med. 2003 May;9(5):223-8 with permission from Elsevier.) 
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2.2.1 Adhesion, invasion and proliferation of endometrial cells 
Apart from only being present in the peritoneal cavity, endometrial cells are able to 
attach and invade the peritoneum and proliferate to create endometriotic lesions. It 
appears that both endometrial stromal cells and epithelial cells are able to attach to the 
peritoneal membrane (Witz, et al., 2001). Evidence of invasion of endometriotic lesions 
has also been demonstrated by Spuijbroek et al. (Spuijbroek, et al., 1992). The invasion 
of endometrial cells requires local degradation of the extracellular matrix (ECM) by 
matrix metalloproteinases (MMPs). In normal endometrium MMPs and their inhibitors, 
tissue inhibitors of matrix metalloproteinases (TIMPs), are needed for the control of 
tissue breakdown and a higher expression of these factors is seen during the menstrual 
phase (reviewed in (Pitsos and Kanakas, 2009)). Aberrant expression of MMPs and 
TIMPs has been seen in endometriosis with increased levels of MMP-9 in endometrium 
from women with endometriosis (Collette, et al., 2006). Also, the ratio of MMP-
9/TIMP-1 protein and mRNA levels were increased. This is strengthened by other 
studies, which have found decreased levels of TIMP-1 in peritoneal fluid 
(Szamatowicz, et al., 2002) and higher mRNA levels of MMP-2, -9 and -14 in 
endometriotic cells (Ueda, et al., 2002). In addition, MMPs are regulated by steroid 
hormones and cytokines, which are important regulators of endometriosis (reviewed in 
(Pitsos and Kanakas, 2009)). Interleukin-1 (IL-1) increases the secretion of MMP-3 in 
endometrial cells from women with endometriosis (Sillem, et al., 2001). Endometrial 
stromal cells treated with IL-8 showed increased MMP-2 and -9 activities and 
invasiveness (Mulayim, et al., 2004). 
 
Cells from endometriotic lesions have demonstrated increased capacity to proliferate 
compared to endometrial cells from women without endometriosis (Li, et al., 1993, 
Nisolle, et al., 1997). Klemmt et al. demonstrated that stromal cells from endometriotic 
lesions and from the endometrium of women with endometriosis had an increased 
adhesive and proliferative ability in response to specific ECM components (Klemmt, et 
al., 2007).  
 
Cell adhesion molecules facilitate cell-cell and cell-ECM adhesion. It has been 
suggested that cell adhesion molecules, such as integrins and cadherins, are involved in 
the development of endometriosis. The adhesion of endometrial cells in endometriosis 
is likely to be modulated in connection with ECM molecules. Integrins, cadherins, 
laminin and fibronectin have been observed in the endometrium and in endometriosis 
(Beliard, et al., 1997, van der Linden, et al., 1994, van der Linden, et al., 1994). Beliard 
et al. reported a stronger expression of integrin α5 by stromal cells in endometriosis, 
compared to stromal cells in healthy endometrium (Beliard, et al., 1997). Furthermore, 
decreased expression of N-cadherin (Van Patten, et al., 2010), but also E-cadherin  and 
CD44 (Poncelet, et al., 2002), have been observed in peritoneal endometriosis.  Other 
factors, such as L1 cell adhesion molecule (L1CAM) may also be involved in the 
development of endometriosis (Finas, et al., 2008). Inhibition of L1CAM in an 
endometriosis epithelial cell line leads to decreased cell proliferation and invasion 
(Agic, et al., 2010).  
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2.2.2 Estrogenic effects 
It has been known for some time that estrogen is involved in the pathogenesis of 
endometriosis. Aromatase is the key enzyme in the biosynthesis of estrogen, which is 
important for the establishment and growth of endometriosis. Expression of aromatase 
has been found in endometriotic lesions and endometrium from women with 
endometriosis (Noble, et al., 1996, Velasco, et al., 2006), creating an estrogenic 
environment. Also, stimulation of endometriotic stromal cells with IL-6 lead to a higher 
aromatase activity (Velasco, et al., 2006).  
 
The survival and growth of endometriotic lesions requires an adequate blood supply, 
indicating an important role of angiogenesis in endometriosis. Estrogen has a function 
in regulating angiogenic growth factors (reviewed in (Hyder and Stancel, 1999)). 
Increased levels of angiogenic factors, such as vascular endothelial growth factor 
(VEGF) which is one of the most potent angiogenic factors, are found in the peritoneal 
fluid of endometriosis patients with advanced disease (Mahnke, et al., 2000). In 
addition, peritoneal fluid from women with endometriosis increased the expression of 
VEGF in endometrial cell cultures (Cosin, et al., 2010).  McLaren et al. observed that 
VEGF production by macrophages in the peritoneal fluid was increased after 
stimulation with estrogen and progesterone (McLaren, et al., 1996). Macrophage 
migration inhibitory factor (MIF), a potential mediator of angiogenesis, is increased in 
the peritoneal fluid from women with endometriosis and affects the proliferation of 
endothelial cells (Kats, et al., 2002). 
 
Estrogen also has a role in apoptosis. Removal of estrogen in cell cultures was 
associated with decreased cell viability and increased number of apoptotic cells (Song, 
et al., 2002). Estrogen also increases the phosphorylation of Akt, a regulator of 
apoptosis and cell survival (Guzeloglu Kayisli, et al., 2004). Impaired apoptosis in 
endometriotic cells of women with endometriosis may contribute to the pathogenesis of 
the disease. In healthy women, apoptosis is important to maintain the cellular 
homeostasis during the menstrual cycle (Kokawa, et al., 1996). In women with 
endometriosis, increased expression of anti-apoptotic factors and decreased expression 
of pro-apoptotic factors have been reported, supporting an anti-apoptotic phenotype of 
endometriotic cells (reviewed in (Agic, et al., 2009)). Gebel et al. demonstrated 
decreased apoptosis in eutopic endometrium in women with endometriosis compared to 
controls, which was further decreased in ectopic endometrium  (Gebel, et al., 1998).  
 
 
2.2.3  Inflammation and immune response 
Increased inflammation and altered immune functions have been observed in women 
with endometriosis. A complex network of locally produced cytokines and immune 
cells have been proposed to modulate the growth and inflammatory behavior of the 
endometriotic implants (reviewed in (Osuga, et al., 2010)). An increased number of 
activated macrophages have been seen in the peritoneal fluid of endometriosis patients 
(Dunselman, et al., 1988, Keenan, et al., 1995).  Oosterlynck et al. reported a decreased 
natural killer (NK) cell activity and cytotoxicity in peritoneal fluid (Oosterlynck, et al., 
1991). A reduction of activated T-cells (Ho, et al., 1995) and mature dendritic cells 
(Schulke, et al., 2009) have been seen in women with endometriosis. In addition, 
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peritoneal fluid from endometriosis patients contained a significantly higher NK cell 
suppressive activity than peritoneal fluid from fertile controls (Oosterlynck, et al., 
1993).This may partly explain the increased survival of endometriotic cells in the 
peritoneal cavity. 
 
Inflammatory cytokines play a central role in the regulation of cell proliferation, 
activation, motility, adhesion, chemotaxis and morphogenesis. Several cytokines, such 
as IL-1, IL-5, IL-6, IL-8, IL-15, monocyte chemotactic protein-1 (MCP-1), TNF-α, 
transforming growth factor-β (TGF-β) and Regulated on Activation, Normal T-cell 
Expressed and Secreted (RANTES) have been implicated in the pathogenesis of 
endometriosis (reviewed in (Lebovic, et al., 2001)). It has been observed that the level 
of some cytokines in peritoneal fluid and serum correlates to the severity of the disease. 
Expression of TNF-α, IL-8 and MCP-1 was higher in early stage of endometriosis and 
decreased with more advanced disease, while TGF-β expression decreased with the 
severity of the disease (Pizzo, et al., 2002). RANTES was also increased in the 
peritoneal fluid in women with more severe disease (Khorram, et al., 1993).  
 
It has been reported that endometrial cells stimulated with IL-8 showed increased 
survival  in vitro  (Gazvani, et al., 2002). Iwabe et al. demonstrated that TNF-α 
stimulated proliferation of endometriotic stromals cells through the induction of IL-8 
(Iwabe, et al., 2000). Moreover, TNF-α increases the adherence of stromal cells to 
mesothelial cells in culture (Zhang, et al., 1993). Interestingly, TNF-α has a 
proliferative effect on endometrial cells from endometriosis patients, but not on 
endometrial cells from healthy women (Braun, et al., 2002). The abnormalities seen in 
the peritoneal fluid from endometriosis patients may also be linked to endometriosis-
associated infertility.  
 
 
2.2.4 Autoimmune features 
It has been proposed that endometriosis is associated with autoimmune disease, due to 
elevated autoantibody titers in women with the disease (Gleicher, et al., 1987). Sinaii et 
al. have observed higher rates of autoimmune diseases, such as rheumatoid arthritis 
(RA), systemic lupus erythematosus (SLE) and Sjögren´s syndrome, in endometriosis 
patients (Sinaii, et al., 2002). Several mechanisms, such as familial occurrence, T- and 
B-cell abnormalities, tissue damage and altered apoptosis, are common in both 
endometriosis and autoimmune diseases (reviewed in (Matarese, et al., 2003, Nothnick, 
2001)).  
 
 
2.2.5 Endometrial stem cells 
Recently, it has been suggested that endometrial stem/progenitor cells are not only 
involved in the regeneration of endometrium, but  also the pathogenesis of 
endometriosis (reviewed in (Gargett, 2004)). It may be possible that in women 
developing endometriosis, inappropriately shed stem/progenitor cells reach the 
peritoneal cavity by retrograde menstruation, and thereby develop endometriotic  
implants (reviewed in (Sasson and Taylor, 2008)). The first evidence of 
stem/progenitor cells in the endometrium came from cloning studies, when Chan et al. 
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observed that a small population of human endometrial epithelial and stromal cells 
possessed clonogenic activity in vitro (Chan, et al., 2004). It has also been shown that 
cells from the endometrium can differentiate into mesodermal lineages in vitro, such as 
chondrogenic (Wolff, et al., 2007), adipose (Dimitrov, et al., 2008), myogenic, and 
osteogenic (Schwab and Gargett, 2007) cell types, suggesting that these cells are 
multipotent adult stem cells with an activity similar to mesenchymal stem cells. 
Another possibility is that bone marrow-derived stem cells could have a role in both the 
regeneration of the endometrium and in endometriosis (Du and Taylor, 2007). 
 
 
2.3 INFERTILITY AND ENDOMETRIOSIS 
Several studies have found an association between endometriosis and infertility 
(reviewed in (de Ziegler, et al., 2010)). Endometriosis is present in 20-40% of women 
with infertility (1994, Strathy, et al., 1982, Verkauf, 1987). A meta-analysis by 
Barnhart et al. reported that women with endometriosis have ≤54% reduction in 
pregnancy rate after in vitro fertilization (IVF), compared to women with tubal factor 
infertility (Barnhart, et al., 2002). Moreover, decreased pregnancy rate per cycle, 
pregnancy per transfer and implantation rate have been observed in endometriosis 
patients (Arici, et al., 1996, Simon, et al., 1994). Women with endometriosis stage 
III/IV seem to have a worse prognosis for IVF/intracytoplasmic sperm injection (ICSI) 
treatment (Kuivasaari, et al., 2005). 
 
The underlying reason for endometriosis-associated infertility is debated. Several 
mechanisms have been proposed, such as distorted pelvic anatomy, endocrine and 
ovulatory abnormalities, altered peritoneal function, poor oocyte quality and defective 
implantation capacity (figure 2).  In vitro studies of fertilized oocytes from 
endometriosis patients showed a decrease in the number of blastomeres and an increase 
in the percentage of arrested embryos compared with controls (Pellicer, et al., 1995), 
indicating a reduced quality of embryos from endometriosis patients. Oocyte donation 
studies report lower implantation rates in recipients who received oocytes from women 
with endometriosis (Simon, et al., 1994). Furthermore, cytokines in the peritoneal fluid 
are believed to be involved in the endometriosis-associated infertility. Since the ovaries 
and the fallopian tube are exposed to peritoneal fluid, different factors in the peritoneal 
fluid could have influence on reproductive functions. Thus, early embryos are exposed 
to the peritoneal fluid, which could be toxic for the preimplantation embryo (Morcos, et 
al., 1985). This is strengthened by Damewood et al., who reported that serum from 
endometriosis patients decreases the growth of mouse embryos (Damewood, et al., 
1990). High levels of TNF-α and MIF have been found to reduce sperm motility in 
vitro (Carli, et al., 2007, Said, et al., 2005) and high levels of RANTES have a negative 
effect on the sperm fertilizing ability (Barbonetti, et al., 2008). TNF-α also reduced 
maturation of porcine oocytes (Ma, et al., 2010).  
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Figure 2. Proposed mechanisms of endometriosis on fertility. 
 
 
2.3.1 Ovarian reserve 
The ovarian reserve has been shown to decrease with increasing age, leading to a lower 
reproductive capacity (reviewed in (te Velde, et al., 1998)). Several different techniques 
have been proposed for the assessment of the ovarian reserve. Commonly used tests are 
the measurement of follicle stimulating hormone (FSH), estradiol and inhibin B in 
serum on cycle day 3 of the menstrual cycle and the number of antral ovarian follicles 
(antral follicle count) with ultrasound. Another marker of the ovarian reserve is the 
serum level of anti-mullerian hormone (AMH) (van Rooij, et al., 2002). AMH is 
produced by preantral and small antral follicles and may act as a paracrine regulator of 
early follicular growth (Weenen, et al., 2004). The concentration of AMH is not 
influenced by the menstrual cycle (Streuli, et al., 2009) or oral contraceptives (Streuli, 
et al., 2008), making it possible to measure AMH levels at any time of the menstrual 
cycle during hormonal treatment. Higher levels of AMH in serum have been associated 
with a higher number of retrieved oocytes (Seifer, et al., 2002) and a higher pregnancy 
rate (Hazout, et al., 2004). Reduced levels of AMH have been reported in infertile 
women with endometriosis (Shebl, et al., 2009).  
 
 
2.4 ENDOMETRIOSIS-ASSOCIATED MALIGNANCY 
Although endometriosis is a benign disease, it has been considered to have malignant 
characteristics. Endometriosis involves attachment and invasion of healthy tissue, loss 
of control of cell proliferation and is spread both locally and distantly. Furthermore, 
genetic, angiogenic, endocrine and immunological abnormalities have been observed in 
endometriosis patients. In malignancy, these properties are also altered. 
Epidemiological studies show association of different types of malignancy and 
endometriosis, such as ovarian cancer, breast cancer, colon cancer, endocrine tumours, 
brain tumours and non-Hodgkin´s lymphoma (Bertelsen, et al., 2007, Brinton, et al., 
1997, Brinton, et al., 2005, Gemmill, et al., 2010, Hornstein, et al., 1997, Melin, et al., 
2006, Olson, et al., 2002). Interestingly, Melin et al. observed better survival in 
endometriosis patients with cancer compared to women with the same form of cancer 
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but without endometriosis, especially those with breast and ovarian cancer (Melin, et 
al., 2010). 
 
 
2.4.1 Ovarian cancer 
Several studies have found associations between endometriosis and ovarian cancer 
(Brinton, et al., 1997, Brinton, et al., 2005, Melin, et al., 2006). In a Swedish population 
study, the risk of ovarian cancer was increased 4.2-fold in subjects with a long-standing 
history of ovarian endometriosis (Brinton, et al., 1997). Melin et al. reported that 
women with early diagnosis and long-standing endometriosis had a higher prevalence 
of ovarian cancer (Gemmill, et al., 2010, Melin, et al., 2006). In addition, cancer was 
found more often in the ovaries when endometriosis was present in the ovary (Stern, et 
al., 2001). Clear cell and endometrioid carcinoma were the most commonly seen types 
of ovarian cancers in endometriosis patients (Fukunaga, et al., 1997, Ogawa, et al., 
2000, Stern, et al., 2001). The most frequent location for coexistence of endometriosis 
and cancer is the ovaries, which has been estimated to occur in 0.7-5.0% of all cases 
with ovarian cancer (Erzen and Kovacic, 1998, Ogawa, et al., 2000, Stern, et al., 2001). 
 
 
2.4.2 Transformation of endometriosis into ovarian cancer 
The mechanism by which endometriosis is transformed into malignancy is unclear. 
Two theories have been suggested, seen in figure 3 (reviewed in (Varma, et al., 2004)). 
It is possible that endometriosis is directly transformed into ovarian cancer via atypical 
endometriosis. Another theory is that endometriosis and ovarian cancer share common 
mechanisms and/or predisposing factors, such as an inflammatory environment, genetic 
susceptibility and hormonal factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Two possible pathways of the transformation of endometriosis into ovarian cancer.  
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Ovarian cancer derived from the malignant transformation of endometriosis has been 
referred to as endometrioisis-associated ovarian cancer (EAOC). Atypia has been 
observed in EAOC (Fukunaga, et al., 1997, Prefumo, et al., 2002) and Ogawa et al. 
reported evidence of transformation from endometriotic lesions to atypical 
endometriosis and further into carcinoma (Ogawa, et al., 2000). About 60% of cases of 
EAOC occur with endometriosis adjacent to the cancer or direct transformation from 
the endometriotic lesion (Erzen and Kovacic, 1998, Modesitt, et al., 2002). Banz et al. 
observed equally regulated genes in endometriosis and EAOC (Banz, et al., 2010). 
 
A variety of different molecular changes have been suggested to be involved in the 
malignant transformation of endometriosis. Genetic alterations are a well-known 
characteristic of malignancy. Especially alterations in oncogenes and tumor suppressor 
genes, such as p53 alterations, Kirsten rat sarcoma viral oncogene homologue (K-ras) 
mutations and Phosphatidylinositol-3, 3, 5,- triphosphate 3-phosphate (PTEN) 
silencing, have been suggested to play a role in malignant transformation of 
endometriosis. In a mouse model of endometrioid ovarian cancer, PTEN deletion and 
K-ras activation, gave rise to endometriosis-like lesions, which further developed into 
endometrioid ovarian carcinoma (Dinulescu, et al., 2005). Mutations in PTEN have 
also been observed in endometriomas, as well as in ovarian cancer (Sato, et al., 2000) 
and K-ras mutations have been seen in endometrioid (Amemiya, et al., 2004) and clear 
cell carcinoma (Okuda, et al., 2003). Sáinz de la Cuesta et al. demonstrated an increase 
in expression of p53 in the transformation from atypical endometriosis to ovarian 
cancer (Sainz de la Cuesta, et al., 2004). Furthermore, several studies have reported loss 
of heterozygosity (LOH) as an event in the malignant transformation of endometriosis 
(Jiang, et al., 1998, Prowse, et al., 2006, Sato, et al., 2000). 
 
Malignant transformation is also influenced by the microenvironment. The 
inflammatory environment in endometriosis, with increased levels of cytokines, growth 
factors and hormones, has been proposed to play a role in the malignant transformation 
of endometriosis (reviewed in (Nezhat, et al., 2008, Varma, et al., 2004)). Ness et al. 
reported similar alterations in inflammatory and immune response in women with 
endometriosis and ovarian cancer (Ness, 2003). In addition, resistance to apoptosis, 
angiogenesis and the ability to invade is shared between endometriosis and malignancy.  
 
 
2.5 GENETIC STUDIES OF ENDOMETRIOSIS 
Several studies have indicated a genetic contribution in endometriosis. Familial studies 
have shown a six to nine fold increase in risk of endometriosis among relatives 
(reviewed in (Kennedy, et al., 2001)). In addition, Stefansson et al. reported a relative 
risk of 2.20 for sisters and 1.56 for cousins to develop endometriosis (Stefansson, et al., 
2002). Twin studies (Moen, 1994) and animal studies (Zondervan, et al., 2004) also 
support the role of genetics in the pathogenesis of endometriosis. However, not only 
genes seem to contribute to endometriosis, but also environmental factors, indicating 
that endometriosis is a complex disease (Kennedy, 1999). Treloar et al. reported that  
50% of the variance of susceptibility to endometriosis in Australian twins was 
attributed to genetic factors (Treloar, et al., 1999). 
 
 14 
 
2.5.1 Genetics of complex diseases 
Diseases which do not exhibit classical Mendelian inheritance are described as complex 
diseases. Complex diseases are relatively common in the general population and seem 
to cluster within families. In addition, complex diseases are believed to be influenced 
by several genetic and environmental factors, as well as interactions among them. The 
common variant hypothesis suggests that common genetic variants with relatively high 
frequency, but low penetrance, are the major contributors to common complex diseases 
(reviewed in (Altshuler, et al., 2008)). However, rare variants, with a low frequency 
and high penetrance also contribute to complex diseases (Stratton and Rahman, 2008). 
Most likely, the genetic etiology is based on a combination of both rare and common 
variants.   
 
The two most common methods used to investigate complex diseases are linkage and 
association studies. These two methods basically rely on the same principle; i.e. co-
inheritance of adjacent DNA variants. Linkage studies identify haplotypes that are 
inherited for several generations within families and association studies investigate the 
retention of adjacent DNA versions for many generations in cases and controls 
(reviewed in (Cardon and Bell, 2001)).  
 
 
2.5.2 Sequence variations in the genome 
Even though humans are said to be 99.9% identical in respect to DNA, a lot of different 
variations in the human genome have been observed. Genetic variation can explain the 
different phenotypes among individuals, although the majority of variants are believed 
to be neutral with no phenotypic effect. Common variations have a minor allele 
frequency (MAF) of at least 1%, while rare variations (mutations) have a MAF less 
than 1% (reviewed in (Frazer, et al., 2009)). Genetic variations include single 
nucleotide polymorphisms (SNPs) and simple sequence repeats (SSRs, also known as 
micro- and minisatellites), as well as structural variants, such as insertions and deletions 
(indels), inversions, block substitution and copy number variants (CNV) (reviewed in 
(Feuk, et al., 2006)).  
 
SNPs are the most common genetic variation, where a single nucleotide is changed, 
inserted or deleted, seen in figure 4. The number of SNPs in the human genome is 
estimated to be around 3.3 million, with an average of 1 SNP in 1000 bases (reviewed 
in (Altshuler, et al., 2008, Frazer, et al., 2009)). SNPs are found both in non-coding and 
coding regions. Synonymous SNPs, localized in coding regions, can cause an amino-
acid change, frame shift or termination of translation, thereby giving a functional effect 
on protein level, or the SNP does not affect the amino-acid sequence. SNPs located in 
non-coding regions, non-synonymous SNPs, could also have a functional effect, due to 
localization in regulatory elements such as gene promotors, enhancers or silencers.  
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Figure 4. Single nucleotide polymorphism (SNP). 
 
 
Association studies investigate the correlation between a genetic variation and a trait, 
thereby comparing the differences in allelic frequency between cases and controls. 
Often the genetic variant lies within a candidate gene, which is chosen due to its 
relevance in the pathophysiology of the disease, or from previously found linkage 
regions. Association between a marker and a phenotype can be due to two reasons; 
either by marking the causal allele itself or by marking neighboring variants in linkage 
disequilibrium (LD). LD defines genetic variants positioned close, which tend to be 
inherited together, and the combination on those linked variants are called haplotypes 
(Daly, et al., 2001). Associated variants need to be replicated in several independent 
populations and functional studies are required to determine the effect of the variant. 
 
 
2.5.3 Linkage and GWAS studies in endometriosis 
Genome-wide association studies (GWAS) makes it possible to genotype a million 
SNPs in one individual at a time (reviewed in (McCarthy and Hirschhorn, 2008)). Until 
today, only a few linkage studies and GWAS have been performed in the field of 
endometriosis (reviewed in (Montgomery, et al., 2008)). Treloar et al. reported a 
susceptibility locus for endometriosis on chromosome 10q26 and a suggestive linkage 
on chromosome 20p13 (Treloar, et al., 2005). Another locus on chromosome 7p13-15 
has been found in linkage studies (Zondervan, et al., 2007) and the locus at 7p15.2 was 
identified in a GWAS performed by Painter et al. (Painter, et al., 2011).  Furthermore, 
the CDKN2BAS locus has been associated with endometriosis in Japanese in a GWAS 
(Uno, et al., 2010) and the region around IL1α on 2q13 has been suggested as a 
candidate (Adachi, et al., 2010). However, in most linkage and GWAS the candidate 
genes and their functional relevance remain to be identified. 
 
 
2.5.4 Candidate genes in endometriosis 
Several different candidate genes have been suggested to be involved in endometriosis, 
including genes involved in inflammation, steroid synthesis, hormone receptors, growth 
factors, adhesion molecules, cell cycle regulation, apoptosis and oncogenesis (reviewed 
in (Falconer, et al., 2007)). Association of polymorphisms in inflammatory genes, such 
as IL-10, IL-16, IL-18, TGF-β, Interferon γ (IFN-γ) and TNF-α, has been observed, 
mostly in Asian populations (Ayaz, et al., 2011, Gan, et al., 2010, Hsieh, et al., 2005, 
Juo, et al., 2009, Kitawaki, et al., 2004, Lakshmi, et al., 2010, Teramoto, et al., 2004). 
Human leukocyte antigen (HLA) genes play a key role in the immune response and are 
highly polymorphic. Association of different HLA variants have been reported in some 
Japanese studies (Ishii, et al., 2002, Kitawaki, et al., 2002), while other studies could 
not find any association (Roszkowski, et al., 2005, Whang, et al., 2006). Studies have 
also reported conflicting results regarding the association of PTPN22 and 
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endometriosis, with two studies showing association (Ammendola, et al., 2008, Gomes, 
et al., 2010) and one showing no association (Ploski, et al., 2009). Many conflicting 
results like these have been found among the association studies, making it difficult to 
conclude the genetic effects in endometriosis. Most studies have small populations with 
poorly-defined control populations. In order to understand more about the genetic 
contribution to endometriosis, larger and more controlled studies are needed (Colhoun, 
et al., 2003, Zondervan, et al., 2002). In addition, the results should be replicated in 
several populations. 
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3 AIMS 
 
The overall aim of this thesis was to study the aetiology and pathophysiology of 
endometriosis, in order to obtain a better understanding of the disease. Furthermore, the 
aim was to investigate the genetic background of endometriosis and genetic linkage to 
other diseases. 
 
The specific aims were: 
 
• To study the cytokine expression profile in follicular fluid from endometriosis 
patients undergoing IVF. (Paper I) 
 
• To investigate a possible shared genetic background between endometriosis and 
RA. (Paper II) 
 
• To evaluate if endometriosis and ovarian cancer shares disease associated 
genes. (Paper III) 
 
• To identify factors involved in adhesion, attachment and invasion in 
endometrium and endometriosis. (Paper IV) 
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4 MATERIAL AND METHODS 
 
4.1 STUDY SUBJECTS 
 
4.1.1 IVF patients (I) 
Serum samples and follicular fluid were collected at the fertility unit (RMC) at the 
Karolinska University Hospital, Sweden. The study included 34 women with 
laparoscopically-verified endometriosis. In addition, a control group, consisting of 38 
women with tubal factor infertility and with no signs of endometriosis upon 
laparoscopy, was used for comparison. Both groups were similar with respect to age, 
body mass index (BMI), smoking and duration of infertility. All women underwent IVF 
and embryo transfer according to standard protocols.  
 
 
4.1.2 Belgian cases and controls (II, III) 
In study II and III, a sample set of 1149 women (798 endometriosis patients and 351 
controls) was used.  All women were Caucasian and had undergone laparoscopy for 
subfertility with or without pain at the Leuven University Hospital, Leuven, Belgium 
during 1998-2007.  Peripheral blood samples (n=948; 660 endometriosis patients and 
288 healthy controls) were collected and peritoneal biopsies (n= 229; 161 
endometriosis patients and 68 controls) were taken during surgery. From some patients 
and controls both blood sample and tissue were obtained. The absence of endometriosis 
was confirmed laparoscopically in control patients (age 32 +/- 5 years; BMI 23.4 +/- 4). 
Women with endometriosis (age 31 +/- 4 years; BMI 23.2 +/- 4) had either minimal 
(stage I; n=176), mild (stage II; n=116), moderate (stage III; n=88) or severe (stage IV; 
n = 179) disease, staged according to the revised classification system of the American 
Society of Reproductive Medicine (1997).  
 
 
4.1.3 Healthy women and endometriosis patients (IV) 
Endometrial biopsies from healthy volunteers were taken at the Karolinska University 
Hospital, Sweden in both the proliferative and the secretory phase of the menstrual 
cycle. All women had regular menstrual bleeding and had not used any hormonal 
medication or an IUS at least 3 months prior to recruitment. Endometrium and 
endometriomas from endometriosis patients were collected during both the 
proliferatory and the secretory phase at Danderyds Hospital and Södersjukhuset, 
Sweden, and the University Hospital of Florence, Italy.  The endometriosis patients had 
not used any IUS or hormonal medication 3 months prior to recruitment. Endometrial 
biopsies were taken with a Randall curette or a pipelle. The biopsies were divided and 
placed in RNA later for RNA isolation and formaldehyde/paraformaldehyde for 
immunohistochemical studies. Endometrial dating was performed histopathologically, 
to verify the phase of the menstrual cycle, according to Noyes criteria (Noyes, et al., 
1975).  
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4.2 OVARIAN STIMULATION PROTOCOL (I) 
All patients followed the long Gonadotrophin releasing hormone agonist (GnRHa) 
protocol (Fried, et al., 1996). GnRHa was administered (6x200 μg/day) (Suprefact®, 
Hoechst AB, Stockholm, Sweden), starting on day 21 of the menstrual cycle. It was 
reduced to half of the dose after the start of FSH injections. Down regulation was 
verified by vaginal ultrasound scanning, followed by administration of recombinant 
FSH (75-300 IU/day) (Gonal-F®, Serono Nordic AB, Sollentuna, Sweden). Starting 
dose of FSH was generally 150 IU up to age 35 and 225 IU above age 35, unless 
previous FHS stimulation during IVF indicated otherwise. Endometrial growth and 
follicular development were followed by vaginal ultrasonography, together with serum 
estradiol levels. After adequate stimulation, i.e. a controlled rise of serum estradiol and 
a leading follicle diameter of at least 17 mm, human Chorionic Gonadotrophin (hCG) 
(Profasi®, Serono Nordic AB, Sollentuna, Sweden) was administered. Oocyte retrieval 
was performed approximately 35 hours later by transvaginal ultrasound-guided follicle 
aspiration. Progesterone (3x400 mg/day) (Progesteron MIC APL, Sweden) was given 
until pregnancy test, and with a positive test, continued for 8 weeks after embryo 
transfer. 
 
 
4.3 EXPRESSION ANALYSIS 
 
4.3.1 Hormonal assays (I) 
The concentration of AMH in serum and follicular fluid was measured by enzyme 
immunoassay (EIA) (A16507, Immunotech, Marseille, France). Estradiol and FSH in 
follicular fluid were determined by chemiluminescent enzyme immunometric assay 
(LKE21 resp. LKFS1, Diagnostic Products Corporation, California, USA). The 
estradiol samples were diluted 1:1 000 before analysis. All assays were done according 
to manufacturer’s protocol.  
 
 
4.3.2 Cytokine assays (I) 
The level of TNF in follicular fluid was determined by immunoradiometric assay 
(IRMA), according to manufacturer’s protocol (KIC1751, Biosource, California, USA). 
 
 
4.3.3 Real Time RT-PCR (IV) 
RNA extraction was performed using a dismembranation apparatus (Retsch KG, Haan, 
Germany) together with TRIZOL® reagent (Invitrogen, Carlsbad, CA, USA). RNA 
was treated with RQ1 RNase- free DNase (Promega Biotech AB, Stockholm, Sweden) 
before cDNA preparation with SuperscriptTM II RNase H- Reverse Transcriptase Kit 
(Invitrogen, Carlsbad, CA, USA). RNA levels were quantified with RealTime RT-
PCR, using the Applied Biosystems 7300 RealTime PCR System (Applied Biosystems, 
Foster City, CA, USA). Primers and probes were purchased from available Taqman 
gene expression assays (Applied Biosystems).  
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The threshold cycles (CT), where an increase in reporter fluorescence above the 
baseline signal could first be detected, were determined. 18S was used as endogenous 
control. The mean CT value of 18S was used for normalization and was subtracted 
from the mean CT value of the respective gene, to obtain ∆CT values.   
 
 
4.3.4 Immunohistochemistry (IV) 
For immunohistochemical analysis a panel of antibodies has been used (for detailed 
information, see paper IV). Biopsies were fixed, paraffin-embedded and sectioned. All 
staining was performed with the MACH 3TM Mouse-Probe HRP-polymer kit or MACH 
3TM Rabbit-Probe HRP-polymer kit (Biocare Medical, CA, USA). Stainings were 
developed using DAB and counterstained with Mayer´s hematoxylin. Negative controls 
were performed by omitting the primary antibody or by using primary isotype-matched 
immunoglobulins; Dako Universal Negative Control Mouse (N1698, Dako, 
Carpinteria, CA, USA) and ChromPure Rabbit IgG (011-000-003, Jackson 
Immunoresearch, West Grove, PA, USA). Sections were analysed in a Zeiss Axiovert 
200M microscope (Zeiss, Göttingen, Germany) and images were captured with 
Qcapture, version 3.1.1. (QImagin, Surrey, BC, Canada). 
 
For all immunohistochemical stainings, the intensity of staining and the number of 
positive cells were observed. Scoring was done blindly by 2 independent observers. 
The intensity of staining was graded as 0= no staining, 1= weak staining, 2= moderate 
staining and 3= strong staining. The percentage of stained cells was graded as 
following; 0= no staining, 1= <10%, 2=11-50%, 3= 51-80% and 4= >81%. The final 
score was calculated by multiplying the two scores.  
 
 
4.4 GENETIC ANALYSIS 
 
4.4.1 Genotyping (II, III) 
Taqman allelic discrimination assays were performed according to manufacturer´s 
protocol (Applied Biosystems, Carlsbad, USA) with fluorescent-labeled allele-specific 
probes. After PCR the plates were read in a 7900 HT Fast-Real Time PCR system 
(Applied Biosystems) and analyzed with the SDS 2.2 software (Applied Biosystems).  
 
 
4.4.2 Association analysis (II, III) 
Case-control based associations were performed using three different models; the co-
dominant model, the dominant-recessive model and allelic model. In paper II and III, 
the allelic model is presented. 
 
 
4.4.3 Haploview (II, III) 
The Haploview software 4.2 (Cambridge, MA, USA) was used to investigate linkage 
disequilibrium (LD) between SNPs. Permutation test (10 000 permutations) were used 
to correct for multiple testing.  
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4.5 STATISTICAL ANALYSIS 
All statistical analyses were performed with the statistical package Graphpad Prism 
(Graphpad Software Inc., San Diego, USA). In paper I, the Mann-Whitney U-test and 
Fisher´s exact test was used for comparisons between women with and without 
endometriosis. Outliers were identified with Grubb´s outlier detection test and 
correlations were assessed by Spearman´s rank correlation test. In paper II and III, 
Bonferroni correction was used for multiple testing of SNPs. The Kruskal-Wallis test 
was applied in paper IV, to compare healthy endometrium, endometrium from 
endometriosis patients and endometriomas during the menstrual cycle. P-values less 
than 0.05 were considered significant. 
 
 
4.6 ETHICAL PERMISSION 
Permission from local ethics committees in Sweden, Italy and Belgium was obtained 
for all studies. 
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5 RESULTS AND DISCUSSION 
 
5.1 PAPER I- IVF OUTCOME IN WOMEN WITH ENDOMETRIOSIS IN 
RELATION TO AMH AND INFLAMMATORY MARKERS 
Many women with endometriosis suffer from infertility. It has been suggested that the 
increased inflammatory activity seen in endometriosis contributes to the reduced 
reproductive potential (reviewed in (Halis and Arici, 2004)). The IVF outcome was 
investigated in correlation to levels of AMH and inflammatory markers in IVF patients 
with endometriosis compared to a control group with tubal factor infertility. It was 
observed that women with endometriosis had significantly lower levels of AMH in 
both serum and follicular fluid. In addition, levels of the pro-inflammatory markers 
TNF-α, IL-15 and granulocyte-macrophage stimulating factor (GM-CSF) were 
increased in follicular fluid, while levels of the anti-inflammatory IL-10 were 
decreased. Women with endometriosis responded well to the IVF-treatment, but had 
lower fertilization rates.   
 
AMH is considered to be an indicator of the ovarian reserve, and a poor response in 
IVF has been associated with low concentrations of serum AMH (Al-Qahtani and 
Groome, 2006, van Rooij, et al., 2002). The lower levels of serum AMH seen in our 
study, corroborates earlier finding of low levels of serum AMH at cycle day 3 in 
women with minimal/mild endometriosis (Lemos, et al., 2008). A positive correlation 
of AMH levels in follicular fluid with the total number of follicles was also observed. It 
seems possible that the decreased recruitment of follicles in women with endometriosis 
could be due to an altered hormone-cytokine balance. 
 
In this study, increased levels of TNF-α in follicular fluid from endometriosis patients 
was found. These findings support a previous report of increased production of TNF-α 
in cultured granulosa cells from women with endometriosis (Carlberg, et al., 2000). It 
has been shown that TNF-α in follicular fluid correlates to oocyte quality with higher 
levels of TNF-α in poor quality oocytes (Lee, et al., 2000), indicating a role of TNF-α 
in endometriosis-associated infertility. In addition, it has been demonstrated that TNF-α 
regulates AMH in mouse testis (Hong, et al., 2003). It is possible that this regulation 
could also take place in the ovary.  An earlier study by Kilic et al, could not 
demonstrate any differences in TNF-α levels in the follicular fluid from women with 
endometriosis compared to women with unexplained infertility (Kilic, et al., 2007). 
These contradictory results could be due to differences in control groups or 
heterogeneity among endometriosis patients.  
 
Increased levels of inflammatory cytokines are seen in endometriosis (Matarese, et al., 
2003). Our findings regarding increased levels of TNF-α, IL-15 and GM-CSF support 
previous results. This inflammatory environment is further supported by decreased 
levels of the anti-inflammatory cytokine IL-10 seen in our study. This altered cytokine 
balance may not only affect the folliculogenesis and oocyte development, but also the 
fertilization process. For example, TNF-α has been reported to influence sperm motility 
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in vitro and to reduce the maturation of porcine oocytes (Ma, et al., 2010, Said, et al., 
2005). Thus, cytokine levels may be important in endometriosis-associated infertility. 
 
Our results indicate that women with endometriosis have a poor IVF outcome 
compared to controls. The diminished ovarian reserve may be due to an increased 
inflammatory activity in the ovarian follicles. However, the mechanism of this action 
needs to be evaluated.    
 
 
5.2 PAPER II- RA SUSCEPTIBILITY GENES AND ENDOMETRIOSIS 
The pathogenesis of endometriosis is still unclear, although evidence suggests that 
inflammation plays an important role in the disease. Several inflammatory factors, such 
as TNF-α, RANTES and IL-8 are up regulated in peritoneal fluid from women with 
endometriosis (Khorram, et al., 1993, Pizzo, et al., 2002) and abnormalities in the 
immune system have been observed (reviewed in (Osuga, et al., 2010)). Several of 
these alterations, such as B-and T-cell abnormalities and altered apoptosis are also seen 
in patients with autoimmune diseases, such as RA. In addition, reports indicate that 
endometriosis patients have an increased incidence of autoimmune diseases (Sinaii, et 
al., 2002). Lately, it has been indicated that genetics also could contribute to 
development of endometriosis. Therefore, we wanted to investigate genetic similarities 
between molecular and cellular pathways of endometriosis and RA.  
 
Our material consisted of Caucasian women undergoing laparoscopy for subfertility at 
the Leuven University hospital in Leuven, Belgium. Samples were obtained from 798 
patients with endometriosis and 351 healthy controls. We chose to investigate six RA 
associated SNPs, i.e. PTPN22 rs2476601, STAT4 rs10181656, TRAF1-C5 rs3761847, 
CCL21 rs2812378, CD40 rs4810485 and IRF5 rs3807306. No association was found 
between the selected SNPs and endometriosis. 
 
Due to the heterogeneity of endometriosis, the genetic differences between stage I-II 
(minimal-mild) and III-IV (moderate-severe) was explored. Previous studies have 
found different gene expression between different types of endometriosis (Matsuzaki, 
et al., 2006) and differences in cytokine expression have been observed in patients with 
different stages of the disease (Khorram, et al., 1993, Pizzo, et al., 2002). In our study, 
an association between CCL21 rs2812378 and moderate/severe endometriosis was 
found. However, in RA patients an increased frequency was observed with the G allele 
(Orozco, et al., 2010, Raychaudhuri, et al., 2008), while in endometriosis, an increase in 
the A allele was found. This suggests a different role of this SNP in the two diseases. 
Unfortunately, we do not have any record of autoimmune diseases in our material, but 
it would have been interesting to see if endometriosis patients with increased A allele 
had a lower frequency of autoimmune diseases.  
 
In RA, genetic associations have been found with HLA-DRB1 variants. Therefore, two 
RA associated HLA-DRB1 SNPs, rs660895 and rs2395175, were also investigated in 
our material. No association of these SNPs was found in endometriosis as one group; 
although association of rs660895 was observed in patients with moderate/sever disease. 
Previous genetic studies of endometriosis have shown conflicting results regarding 
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HLA-DRB1. Some studies have found associations (Ishii, et al., 2002, Kitawaki, et al., 
2002) while others could not observe any association (Roszkowski, et al., 2005, 
Whang, et al., 2006). These differences may be due to small study populations, poorly 
defined controls or differences in ethnicity. Most genetic studies of endometriosis 
include very few individuals, therefore making it difficult to establish associations, 
especially associations with low genetic effect. Also, most associations have only been 
observed in one study population and not replicated in other study populations. Our 
study is one of the largest on endometriosis, although compared to other diseases, it is 
relatively small. However, we have a better power to detect associations than previous 
candidate gene studies. One drawback with our study is that we do not have access to 
another population to replicate our results, but we hope that other research groups with 
genetic material from Caucasian populations will find our studies interesting and 
perform replication of our results. While performing genetic studies, collaborations will 
be needed to obtain larger populations and replication of results. 
 
In this study, association between SNPs in CCL21 and HLA-DRB1 was observed. 
However, we do not know the functional effect of these alleles. We can only speculate 
about the function, relying on previous studies of these genes. Since inflammation is an 
important event in endometriosis, we could assume that CCL21 and HLA-molecules 
are involved in the disease. CCL21 is a chemokine, responsible for recruitment of 
lymphocytes and dendritic cells. In endometriosis, aberrant expression of lymphocytes 
(reviewed in (Osuga, et al., 2010)) and a reduction of mature dendritic cells have been 
observed (Schulke, et al., 2009). Furthermore, CCL21 co-stimulates the expansion of 
naïve T-cells and increases the expression of inflammatory cytokines, such as TNF-α 
and INF-γ (Flanagan, et al., 2004), which are also increased in endometriosis. Increased 
expression of CCL21 has been seen in endometriosis patients and could be a reason for 
this increased inflammatory profile (Chand, et al., 2007). Also, HLA-molecules are 
important in the immune system, by differentiating T-cells and inhibiting the killing of 
NK cells. The expression of major histocompatibility complex (MHC) class I on cells 
protects against NK cell lysis. In endometriosis, a reduction of activated T-cells and 
defective NK cell activity has been observed (Ho, et al., 1995, Oosterlynck, et al., 
1991). In addition, increased expression of HLA class I and II molecules have been 
reported in the endometrium from women with endometriosis compared to controls 
(Baka, et al., 2010, Vernet-Tomas Mdel, et al., 2006). An increased proportion of HLA-
DR positive stromal and glandular epithelial cells have also been reported (Chiang and 
Hill, 1997, Nisolle and Donnez, 1997). This indicates an increased resistance against 
NK cell lysis in endometrial cells in women with endometriosis. 
 
Our results indicate a potential role of CCL21 and HLA in endometriosis. Since the 
HLA region has a high degree of LD, it is difficult to establish the SNP of functional 
value. It is possible that it is not our associated SNPs that give a functional effect, but it 
is in LD with another SNP, causing the effect. Therefore, sequencing of the entire 
region and functional studies are needed to further investigate our findings.  
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5.3 PAPER III- REPLICATION OF OVARIAN CANCER SUSCEPTIBILITY 
GENES IN ENDOMETRIOSIS 
Endometriosis is a benign disease, although it is believed to have malignant 
characteristics. Several epidemiological studies have found an association between 
endometriosis and malignancy, such as ovarian cancer (Brinton, et al., 1997, Melin, et 
al., 2006). However, it is not clear how endometriosis may be transformed into ovarian 
cancer. It has been suggested that endometriosis could transform to cancer via atypical 
endometriosis, or that both diseases could share common mechanisms and/or 
predisposing factors, such as genetic susceptibility. A recent GWAS has reported 
association of several SNPs in the BNC2 gene and ovarian cancer (Song, et al., 2009). 
We therefore wanted to investigate if the same SNPs would be associated to 
endometriosis in our Belgian cases and control samples, to find out if BNC2 could be a 
possible link between endometriosis and ovarian cancer. 
 
In our material, association of the selected SNPs in the BNC2 gene with endometriosis 
could not be observed, either as one group or divided into minimal/mild and 
moderate/severe disease. These results indicate that BNC2 is not associated with 
endometriosis. However, it is possible that we do not have enough power to detect an 
association and replication of our data is needed in another, preferably larger, study 
population.  
 
The function of BNC2 is not clear, but it is believed to participate in mRNA processing 
(Vanhoutteghem and Djian, 2006). Expression of BNC2 has been found in the ovary, 
uterus and testis (Romano, et al., 2004, Vanhoutteghem and Djian, 2004), indicating an 
possible role in reproduction. Perhaps BNC2 is affecting mRNA levels of proteins 
involved in reproduction and thus has a role in endometriosis-associated infertility. To 
explore this possibility, it would be of interest to investigate the expression of BNC2 in 
endometriosis patients and especially in infertile women with endometriosis. It would 
also be interesting to follow the development of ovarian cancer in women with 
endometriosis, to investigate if women developing ovarian cancer have an aberrant 
genetic profile compared to the women who do not develop ovarian cancer. Then we 
can be more certain that BNC2 is not involved in endometriosis. 
 
Other candidate genes have been identified in ovarian cancer, such as genes encoding 
cell cycle proteins, oncogenes and tumor suppressor genes (Goode, et al., 2010, Obata, 
et al., 1998, Quaye, et al., 2009). Pathways regulating processes such as apoptosis, 
angiogenesis and invasion have also been suggested.  Similar alteration has been 
observed in the inflammatory and immune response between ovarian cancer and 
endometriosis (Ness, 2003), indicating a shared inflammatory pathway. There are 
several pathways to investigate and the difficulty is to know where to start. Finding 
proteins with aberrant expression in both diseases may give a clue about which 
pathways to investigate further. It would also be interesting to collect DNA and 
biopsies from patients with endometriosis or ovarian cancer and from patients with both 
diseases, and investigate the possible link between the diseases.  
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5.4 PAPER IV- EXPRESSION OF ADHESION, ATTACHMENT AND 
INVASION FACTORS IN ENDOMETRIOSIS 
To obtain the normal function of the endometrium, different cell properties such as 
adhesion, attachment and invasion are important. However, the same properties may 
also be involved in the establishment of endometriotic lesions. According to Sampson´s 
theory about retrograde menstruation, viable cells are shed into the peritoneal cavity 
(Sampson, 1927). These cells need to be able to adhere to, attach to and invade at 
ectopic sites in order to cause endometriosis. It is possible that factors involved in these 
abilities could be expressed differently in women with endometriosis. Therefore, we 
investigated the expression and localization of six factors involved in the above 
functions, i.e. ApoE, ITGB2, ITGB7, LAMC1, CD24 and JAM-1, in endometrium 
from healthy controls and endometriosis patients as well as in endometriomas. In order 
to investigate if these factors were expressed in a cyclic pattern, we observed mRNA 
and protein expression in both the proliferative and secretory phases of the menstrual 
cycle.  
 
In this study, we found endometrial expression of ApoE, ITGB2, ITGB7 and LAMC1 
in stromal cells and ITGB7, LAMC1, CD24 and JAM-1 in epithelial cells. In 
endometriomas, we could observe expression of ApoE, ITGB2, ITGB7 and LAMC1 in 
sub epithelial regions and CD24 and JAM-1 in epithelial cells. The mRNA levels of 
CD24 and JAM-1 were significantly lower in endometriomas compared with healthy 
endometrium. Also, significantly lower ApoE mRNA levels were seen in the 
proliferative phase in endometriosis patients compared to controls. At protein level, a 
cyclic pattern of CD24 expression was found in epithelial cells from healthy 
endometrium. Protein levels in endometriomas were not quantified due to heterogeneity 
in the staining pattern and low protein expression for all studied factors. The lower 
mRNA and protein levels in endometriomas were surprising, since a higher expression 
of factors with adhesive, attaching and invasive properties was expected. It could be 
possible that the studied factors have other properties that promote the establishment of 
endometriosis when they are down regulated.  
 
ApoE associate with cell surface receptors of plasma lipoprotein particles. It has been 
reported that women with endometriosis have an unfavourable lipid profile with 
increased levels of low density lipoproteins (LDL) (Melo, et al., 2010). Oxidised LDL 
induces MCP-1 production by mesothelial and endometrial cells (Rong, et al., 2002). In 
addition, oxidised LDL triggers inflammatory signalling via toll like receptors (Stewart, 
et al., 2010). Thus, ApoE may play a role in the inflammatory profile seen in women 
with endometriosis. Furthermore, ApoE has been reported to be a marker for cell 
survival and proliferation (Chen, et al., 2005), events that are important in the 
establishment of endometriosis. It would be interesting to further look into the function 
of ApoE in endometriosis, related to inflammation, cell survival and proliferation.  
 
Integrin expression has previously been shown in the endometrium. However, there are 
many different integrins with different functions. Integrins have been observed in 
menstrual endometrium (Koks, et al., 2000, van der Linden, et al., 1994) and TNF-α 
has been shown to increase its adherence (Sillem, et al., 1999). Since TNF-α is an 
important inflammatory mediator in endometriosis, the expression of integins may also 
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be important in the development of the disease. Stronger expression of integrin α5 has 
been observed in stromal cells from endometriosis patients compared to controls 
(Beliard, et al., 1997). Endometriotic stromal cells are able to adhere to laminin in the 
ECM and an aberrant integrin expression may be involved in this adhesion (Adachi, et 
al., 2010). Thus, several observations indicate a possible role of integrins in 
endometriosis.  
 
An increased adhesive capacity has been observed in stromal cells from endometriotic 
lesions and endometrium from women with endometriosis in response to specific ECM 
components (Klemmt, et al., 2007). Laminins are located in the basement membrane of 
the ECM. LAMC1 have been reported to promote adhesion and migration of 
monocytes (Pedraza, et al., 2000). An altered expression of LAMC1 could contribute to 
the aberrant profile of immune cells seen in endometriosis patients. In addition, anti-
Laminin antibodies have been associated with endometriosis-associated infertility 
(Inagaki, et al., 2003) and laminin has been suggested to be involved in the regulation 
of proliferation and differentiation of trophoblast cells during implantation (Klaffky, et 
al., 2001).  
 
Previous studies have observed expression of CD24 and JAM-1 in the endometrium 
(Kim, et al., 2009, Koshiba, et al., 2009). Our findings support these reports. CD24 has 
been suggested to play a role in tumor progression in the ovaries (Choi, et al., 2005). In 
addition, aberrant expression of CD24 and JAM-1 have been found in reproductive 
cancers (Koshiba, et al., 2009, Kristiansen, et al., 2002), indicating that these proteins 
are involved in tumorgenesis. The establishment of endometriosis has similarities to 
malignant processes and therefore CD24 and JAM-1 may also be involved in the 
establishment of the disease, by allowing cells that are shed during menstruation to 
attach to the peritoneal surface and form lesions.  
 
Our study has shown expression of ApoE, ITGB2, ITGB7, LAMC1 CD24 and JAM-1 
in endometrium and endometriomas. However, the function of these proteins in the 
initiation of endometriosis and lesion needs to be investigated further. In addition, it 
would be interesting to evaluate the hormonal regulation of these proteins. 
Furthermore, several of these proteins are involved in malignancy and it would be 
interesting to evaluate their potential role in the transformation of endometriosis to 
ovarian cancer.  
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The following conclusions can be drawn based on the findings of this thesis: 
 
• Women with endometriosis seem to have a diminished ovarian reserve, 
indicated by low levels of AMH and a poor IVF outcome. Furthermore, an 
aberrant inflammatory profile was seen with high levels of TNF-α, IL-15 and 
GM-CSF and low levels of IL-10. Thus, the diminished ovarian reserve could 
be due to the increased inflammatory activity in the ovarian follicles. 
 
• We found an association of CCL21 rs2812378 and HLA rs660895 with 
moderate/severe endometriosis, but not with endometriosis as one group, in a 
Caucasian population. These findings indicate that the genetic background in 
endometriosis might differ depending on type and severity of disease. Our 
results do not indicate shared pathways of endometriosis and RA. 
 
• No association of polymorphisms in the BNC2 gene was observed in 
endometriosis patients, suggesting that SNPs in BNC2 are unlikely to contribute 
to the reported risk of ovarian cancer in endometriosis. 
 
• Endometrium from healthy women and endometriosis patients, together with 
endometriomas, express factors involved in adhesion, attachment and invasion, 
such as ApoE, ITGB2, ITGB7, LAMC1 CD24 and JAM-1. However, their role 
in the development of endometriosis needs to be studied further. 
 
Altogether, these results indicate that the increased inflammatory profile seen in women 
with endometriosis may affect the ovarian reserve and thus lead to infertility problems 
in these women. Changes in the follicular fluid might influence the maturity and quality 
of the oocyte, fertilization, early embryonic development and pregnancy outcome. 
Genetic associations in inflammatory related genes were also found in women with 
moderate/severe disease, further indicating the importance of inflammation in 
endometriosis. In addition, the expression of factors involved in adhesion, attachment 
and invasion may be important in the establishment of endometriotic lesions. These 
factors may also be regulated by inflammatory mediators. 
 
For future studies, it would be interesting to investigate the function of CCL21 in 
endometriosis and to find out if the CCL21 rs2812378 has a functional role in the 
disease. To start with, the expression of CCL21 could be compared to the rs2812378 
alleles, to see the impact of the endometriosis-associated A allele. It would also be 
interesting to investigate other SNPs that are in LD with rs2812378, to see if the 
endometriosis associated SNP(s) could lie elsewhere.   
 
In general, I would like to collect a new sample set of Swedish cases and controls, 
which is larger than our previous material and with more information about the 
patients. It would be interesting to collect data of type and stage of endometriosis, other 
diseases, such as autoimmune diseases and cancer, and environmental factors. From 
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these patients, biopsies and serum samples could also be collected to do follow-up 
functional studies and expression analysis. A GWAS could be used to localize 
candidate genes and our samples from Belgium could be used for replication.  
 
Since we have found expression of different factors involved in adhesion, attachment 
and invasion (ApoE, ITGB2, ITGB7, LAMC1 CD24 and JAM-1), it would be 
interesting to evaluate the possible role of these factors in endometriosis. I would like to 
perform invasion and proliferation assays with cells expressing these markers and 
compare between cells from endometrium from healthy controls and endometriosis 
patients, to see if the function is changed in endometriosis patients. I would also like to 
investigate the hormonal regulation of these factors, especially the effect of estrogen. 
Furthermore, it would be interesting to see if there is any connection between 
stem/progenitor cells and the expression of factors involved in adhesion, attachment 
and invasion. Is it possible that endometrial stem/progenitor cells with increased 
adhesive and invasive properties are shed during menstruation in endometriosis 
patients, but not in healthy women? 
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